TY  - JOUR
AU  - Ramchandren, Radhakrishnan
AU  - Domingo-Domènech, Eva
AU  - Rueda, Antonio
AU  - Trněný, Marek
AU  - Feldman, Tatyana A
AU  - Lee, Hun Ju
AU  - Provencio, Mariano
AU  - Sillaber, Christian
AU  - Cohen, Jonathon B
AU  - Savage, Kerry J
AU  - Willenbacher, Wolfgang
AU  - Ligon, Azra H
AU  - Ouyang, Jing
AU  - Redd, Robert
AU  - Rodig, Scott J
AU  - Shipp, Margaret A
AU  - Sacchi, Mariana
AU  - Sumbul, Anne
AU  - Armand, Philippe
AU  - Ansell, Stephen M
PY  - 2019
DO  - 10.1200/JCO.19.00315
UR  - http://hdl.handle.net/10668/13996
T2  - Journal of clinical oncology : official journal of the American Society of Clinical Oncology
AB  - Nivolumab, an anti-programmed death-1 monoclonal antibody, has demonstrated frequent and durable responses in relapsed/refractory classic Hodgkin lymphoma (cHL). We report results from Cohort D of the CheckMate 205 trial, which assessed nivolumab...
LA  - en
KW  - Adolescent
KW  - Adult
KW  - Aged
KW  - Aged, 80 and over
KW  - Antineoplastic Agents, Immunological
KW  - Cohort Studies
KW  - Female
KW  - Hodgkin Disease
KW  - Humans
KW  - Male
KW  - Middle Aged
KW  - Neoplasm Staging
KW  - Nivolumab
KW  - Young Adult
TI  - Nivolumab for Newly Diagnosed Advanced-Stage Classic Hodgkin Lymphoma: Safety and Efficacy in the Phase II CheckMate 205 Study.
TY  - research article
VL  - 37
ER  -